Flow cytometry aneuploidy and cell cycle indexing as a possible tool for differentiating between CD10 + diffuse large B-cell lymphoma and follicular lymphoma.

Autor: Azoulay D; Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.; Hematology Unit and Laboratories, Galilee Medical Center, Naharia, Israel., Cohen HI; Pathology Unit, Galilee Medical Center, Naharia, Israel., Dementiev E; Pathology Unit, Galilee Medical Center, Naharia, Israel., Eshel E; Hematology Unit and Laboratories, Ziv Medical Center, Safed, Israel., Akria L; Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.; Hematology Unit and Laboratories, Galilee Medical Center, Naharia, Israel., Shaoul E; Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.; Hematology Unit and Laboratories, Galilee Medical Center, Naharia, Israel., Horowitz N; The Ruth and Bruce Rappaport Faculty of Medicine, Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Technion, Israel Institute of Technology, Haifa, Israel.
Jazyk: angličtina
Zdroj: Cytometry. Part B, Clinical cytometry [Cytometry B Clin Cytom] 2020 Sep; Vol. 98 (5), pp. 449-453. Date of Electronic Publication: 2019 Dec 09.
DOI: 10.1002/cyto.b.21861
Abstrakt: Background: Differential diagnosis between diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) becomes a challenge when adequate biopsy is unavailable. The present study aimed to investigate the applicability of DNA cell cycle analysis by flow cytometry (FC) for differentiating between CD10 + DLBCL and FL.
Methods: Data were collected from 57 specimens where CD5 - /CD10 + /light chain restricted B cells were detected. DNA staining was performed using the Coulter DNA Prep Kit. Cell cycle fractions were evaluated by automatic analysis using the ModFit LT software.
Results: Histopathological analysis confirmed the diagnosis of CD10 + FL in 30 specimens (52.6%), CD10 + DLBCL in 24 specimens (42.1%), and CD10 + Burkitt lymphoma in 3 specimens (5.3%). A significantly higher rate of DNA aneuploidy was detected among CD10 + DLBCL than FL specimens (50 vs. 13.3% respectively, p = .003). Likewise, DNA index was significantly higher in CD10 + DLBCL relative to FL (1.26 ± 0.35 vs. 1.04 ± 0.16 respectively, p = .004). Notably, the proportion of cells in the S-phase and proliferative fraction was significantly higher in CD10 + DLBCL than in CD10 + FL (S-phase: 15.97 ± 13.94 vs. 4.43 ± 4.41 mean ± SD, respectively, p < .0001; proliferative fraction: 18.87 ± 15.17 vs. 5.78 ± 7.04 mean ± SD, respectively, p = .0001). Using a receiver operating characteristic analysis, optimal cutoffs for S-phase ≥7% and proliferative fraction ≥9% were determined. These values could be used to differentiate between CD10 + DLBCL and CD10 + FL.
Conclusion: Including DNA cell cycle analysis in the FC lymphoma assessment panel may be of diagnostic value in differentiating between CD10+ DLBCL and FL when adequate biopsy is unavailable.
(© 2019 International Clinical Cytometry Society.)
Databáze: MEDLINE
Externí odkaz: